InfuSystem Holdings, Inc. (NYSE:INFU) Receives Average Recommendation of "Buy" from Brokerages

InfuSystem Holdings, Inc. (NYSE:INFU - Get Free Report) has been given an average recommendation of "Buy" by the five analysts that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, two have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $15.00.The Future of Medical Devices: Two Strong Buys You Can't MissSeparately, Roth Mkm restated a "buy" rating and set a $15.00 price target on shares of InfuSystem in a research note on Tuesday.Read Our Latest Research Report on INFUInstitutional Investors Weigh In On InfuSystemSeveral institutional investors have recently added to or reduced their stakes in INFU. Minerva Advisors LLC increased its stake in InfuSystem by 5.2% during the 4th quarter. Minerva Advisors LLC now owns 1,078,731 shares of the company's stock valued at $9,676,000 after purchasing an additional 52,942 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of InfuSystem by 1.9% during the third quarter. Vanguard Group Inc. now owns 976,177 shares of the company's stock valued at $10,113,000 after buying an additional 18,539 shares during the last quarter. Punch & Associates Investment Management Inc. increased its position in shares of InfuSystem by 1.9% during the fourth quarter. Punch & Associates Investment Management Inc. now owns 824,750 shares of the company's stock valued at $7,398,000 after acquiring an additional 15,000 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of InfuSystem by 2.0% in the fourth quarter. Renaissance Technologies LLC now owns 587,509 shares of the company's stock worth $5,270,000 after purchasing an additional 11,795 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of InfuSystem by 0.8% during the third quarter. Dimensional Fund Advisors LP now owns 569,238 shares of the company's stock valued at $5,898,000 after purchasing an additional 4,430 shares in the last quarter. Hedge funds and other institutional investors own 71.13% of the company's stock. InfuSystem Price PerformanceINFU stock traded up $1.02 during midday trading on Tuesday, reaching $8.60. The company had a trading volume of 180,783 shares, compared to its average volume of 138,861. The stock has a 50 day moving average price of $8.45 and a 200-day moving average price of $9.33. InfuSystem has a 1-year low of $4.61 and a 1-year high of $11.04. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.98 and a quick ratio of 1.59. The company has a market capitalization of $174.89 million, a price-to-earnings ratio of 143.36 and a beta of 1.67. About InfuSystem (Get Free Report)InfuSystem Holdings Inc is a medical technology company that specializes in the rental, management and servicing of infusion pumps and associated devices used primarily for outpatient infusion therapy. The company provides a comprehensive suite of services that includes equipment delivery, setup and retrieval, preventive and corrective maintenance, reprocessing and quality assurance. InfuSystem's offerings are designed to help hospitals, ambulatory surgery centers, oncology clinics and private infusion suites streamline clinical operations and maintain compliance with safety standards. In addition to pump rental and repair services, InfuSystem has expanded into remote patient monitoring solutions.Further ReadingFive stocks we like better than InfuSystemThis makes me furiousElon Musk: This Could Turn $100 into $100,000Silver paying 20% dividend. Plus 68% share gainsREVEALED: Something Big Happening Behind White House DoorsWhat Expenses Can Be Deducted From Capital Gains Tax This Year?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in InfuSystem Right Now?Before you consider InfuSystem, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InfuSystem wasn't on the list.While InfuSystem currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here